« Return to News | Awards & Advancement

Paratek appoints Molnar and Loh to senior positions

Thursday, May 24, 2012 09:00 AM

Paratek Pharmaceuticals of Boston, Mass., has named Dennis Molnar as director, president and CEO, and Evan Loh, MD, as chief medical officer and chairman of the board of directors.  

Molnar, formerly Paratek's vice president of corporate development, has 19 years of experience in the pharmaceutical and biotechnology industries, working in a variety of capacities, including business development, management, finance and consulting. Before joining Paratek in 2001, he served as president of JBI Associates, a software and consulting firm providing services to hospital pharmacies.  Molnar has also served as director of finance and business development at Magainin Pharmaceuticals.  

Loh comes to Paratek from Pfizer where he served as senior vice president of development and strategic operations, worldwide R&D. Prior to joining Pfizer in 2009, Loh was vice president of clinical R&D at Wyeth, where he had global responsibility for scientific, strategic and operational leadership of clinical development efforts across multiple therapeutic areas.  Loh is the 2006 recipient of the Heroes of Chemistry award from the American Chemical Society for his leadership role at Wyeth in the clinical development of Tygacil, a novel glycylcycline broad-spectrum antibiotic. Loh has served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.